Pfizer heads back to school with Trumenba vaccination campaign

Teaching kids to share is usually a parental goal, but a new ad from Pfizer may have some parents rethinking the parameters.

The first campaign for meningococcal group B vaccine Trumenba highlights the dangers of MenB, which can be spread through habits common among teens--including kissing and sharing drinks and food.

The TV ad shows a mother in the hospital with her stricken son, asking “how did we get here?” The ad then goes back through events earlier in evening showing the son sharing food and drinks with several different friends at a party and kissing a girl.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

The spot, which started running last week, is airing in the selected cities of Chicago, Dallas, Houston, Los Angeles, Miami, New York, Philadelphia, Phoenix, Tampa and Washington, D.C. and will also air in physicians’ offices across the country. And its timing was no accident: MenB is responsible for up to half of all U.S. meningococcal disease cases in 17-23 year olds, a Pfizer spokeswoman told FiercePharmaMarketing by email, and in recent years campuses across the country have suffered outbreaks.

“The campaign was designed to reach parents of teens and young adults during the summer and back-to-school season, when many parents are thinking about steps they can take to help protect their child’s health, including vaccination,” she said.

Trumenba is one of two vaccinations to protect against MenB, along with GlaxoSmithKline’s Bexsero. But last year, the CDC's Advisory Committee for Immunization Practices (ACIP) stopped short of granting the pair universal recommendation. The vaccines are recommended for young adults ages 16 to 23, with a preferred age of 16 to 18, which means that doctors decide on an individual basis whether to vaccinate their patients against MenB.

That narrow backing--which limited sales potential--was not what Pfizer and GSK were hoping for. Trumenba recorded $29 million in sales in 2015, up from $16 million in 2014, according to EvaluatePharma.

- watch the ad on

Related Articles:
Pfizer's Trumenba shows 'robust' MenB protection in two PhIII trials
Pfizer touts Trumenba immunogenicity when administered with Menactra, Adacel
With limited ACIP nod, U.S. universities take different approaches to Pfizer, GSK MenB jabs
CDC panel disappoints Pfizer, GSK with limited backing for meningitis B shots
Pfizer, Novartis get MenB ACIP nod--but not the one they're really after​​​​​​​
Ready to spar with Pfizer's meningitis B jab, Novartis gets FDA green light for Bexsero

Suggested Articles

The second of AbbVie’s highly anticipated 2019 blockbuster candidates is here: Its crucial Humira follow-up, Rinvoq.

Bristol-Myers Squibb’s takeover of Celgene hasn’t always gone smoothly, but now a once-left-for-dead centerpiece of that deal is ready to launch.

Investors sued Novo Nordisk in Denmark, claiming it misled the public about trouble plaguing its insulin franchise—and demanding $1.75B in damages.